Lupin completes Phase 3 Trials for Lucentis Biosimilar
The study has achieved its primary endpoint of therapeutic equivalence in visual acuity improvement for wet AMD patients,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lucentis
Enzene Biosciences launches Ranibizumab to treat neovascular AMD
Ranibizumab biosimilar is the company’s seventh biosimilar
Intas and Axantia sign licence and supply agreement for Ranibizumab biosimilar in Middle East
Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in…